Harvard Bioscience Inc expected to post earnings of 3 cents a share - Earnings Preview

Harvard Bioscience

06/11/2024 14:03

* Harvard Bioscience Inc  HBIO.OQ   HBIO.O  is expected
to show a
fall in quarterly revenue when it reports  results on November 7
for the period ending September 30 2024
    * The Holliston Massachusetts-based  company is expected to
report
a 0.2% decrease in revenue to $25.3 million from $25.36 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Harvard Bioscience Inc
is for
earnings of 3 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Harvard
Bioscience Inc is $6.25​, above​ its last closing price
of $2.39. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   0.03        0.05       0.00      Missed  -100
 Mar. 31 0001  0.02        0.02       0.02      Met     -14.3
 Dec. 31 2023  0.05        0.05       0.04      Missed  -20​
 Sep. 30 2023  0.04        0.04       0.01      Missed  -75
 ​​Jun.        0.07        0.06       0.04      Missed  -36.8
 30 2023                                                
 Mar. 31 2023  0.05        0.05       0.06      Beat    20​
 Dec. 31 2022  0.08        0.03       0.04      Beat    20
 Sep. 30 2022  0.07        0.07       -0.01     Missed  -115
 This summary was machine generated November 6 at 14:03 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)